• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Eli Lilly and Company

    5/6/26 5:25:04 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LLY alert in real time by email
    FWP 1 d110421dfwp.htm FWP FWP

    Free Writing Prospectus

    Filed Pursuant to Rule 433

    Registration Statement No. 333-285052

    Dated May 6, 2026

     

    LOGO

    Eli Lilly and Company

    Pricing Term Sheet

    $9,000,000,000 aggregate principal amount of Notes offered, consisting of:

    Floating Rate Notes due 2028 (the “2028 Floating Rate Notes”)

    Floating Rate Notes due 2029 (the “2029 Floating Rate Notes”)

    4.150% Notes due 2029 (the “2029 Notes”)

    4.375% Notes due 2031 (the “2031 Notes”)

    4.650% Notes due 2033 (the “2033 Notes”)

    4.850% Notes due 2036 (the “2036 Notes”)

    5.600% Notes due 2056 (the “2056 Notes”)

    5.700% Notes due 2066 (the “2066 Notes”)

    (The 2028 Floating Rate Notes and the 2029 Floating Rate Notes are collectively referred to as the “Floating Rate Notes.” The 2029 Notes, the 2031 Notes, the 2033 Notes, the 2036 Notes, the 2056 Notes and the 2066 Notes are collectively referred to as the “Fixed Rate Notes.” The Fixed Rate Notes, together with the Floating Rate Notes, are collectively referred to as the “Notes”)

    This pricing term sheet (the “Pricing Term Sheet”) supplements the prospectus supplement issued by Eli Lilly and Company on May 6, 2026 (the “Preliminary Prospectus Supplement”) and the accompanying prospectus dated February 19, 2025 (the “Prospectus”) and supersedes the information in the Preliminary Prospectus Supplement and Prospectus. Other information presented in the Preliminary Prospectus Supplement is deemed to have changed to the extent affected by the changes described herein. Otherwise, this Pricing Term Sheet is qualified in its entirety by reference to the Preliminary Prospectus Supplement and the Prospectus and should be read together with the Preliminary Prospectus Supplement, the Prospectus and the documents incorporated or deemed to be incorporated by reference therein before a decision is made to invest in the Notes.

     

    Issuer:    Eli Lilly and Company
    Trade Date:    May 6, 2026
    Ratings:*   

    Aa3 (Positive) Moody’s

    AA- (Positive) S&P

    Settlement Date:**    May 20, 2026; T+10
    Day Count Convention:   

    Actual / 360 for the Floating Rate Notes

    30 / 360 for the Fixed Rate Notes

    Joint Book-Running Managers:   

    Morgan Stanley & Co. LLC

    Citigroup Global Markets Inc.

    Deutsche Bank Securities Inc.

    Goldman Sachs & Co. LLC
    BNP Paribas Securities Corp.
    J.P. Morgan Securities LLC
    BofA Securities, Inc.
    Barclays Capital Inc.
    Mizuho Securities USA LLC


    Co-Managers:    Loop Capital Markets LLC
    Penserra Securities LLC
    The 2028 Floating Rate Notes   
    Principal Amount Offered:    $750,000,000
    Maturity Date:    May 20, 2028
    Public Offering Price:    100.000% of principal amount, plus accrued interest, if any, from May 20, 2026
    Interest Rate Basis:    Compounded SOFR
    Spread to Compounded SOFR:    +35 basis points
    Interest Payment Dates:    February 20, May 20, August 20 and November 20 of each year, commencing August 20, 2026
    Interest Reset Dates:    Each Floating Rate Interest Payment Date
    Initial Interest Rate:    The initial interest rate will be Compounded SOFR determined on August 18, 2026, plus 35 basis points
    Interest Determination Date:    The second U.S. Government Securities Business Day preceding each Floating Rate Interest Payment Date
    Interest Period:    The period from and including a Floating Rate Interest Payment Date to, but excluding, the immediately succeeding Floating Rate Interest Payment Date (such succeeding Floating Rate Interest Payment Date, the “Latter Floating Rate Interest Payment Date”); provided that (i) the initial interest period for the 2028 Floating Rate Notes will be the period from and including the Settlement Date to, but excluding, the immediately succeeding Floating Rate Interest Payment Date for the 2028 Floating Rate Notes and (ii) the final interest period for the 2028 Floating Rate Notes will be the period from and including the Floating Rate Interest Payment Date immediately preceding the maturity date of the 2028 Floating Rate Notes to, but excluding, the maturity date of the 2028 Floating Rate Notes
    Observation Period:    The period from and including two U.S. Government Securities Business Days preceding the first date of such relevant Interest Period to but excluding two U.S. Government Securities Business Days preceding the Latter Floating Rate Interest Payment Date for such relevant Interest Period for the 2028 Floating Rate Notes; provided that the first Observation Period for the 2028 Floating Rate Notes shall be the period from and including two U.S. Government Securities Business Days preceding the Settlement Date to, but excluding, the two U.S. Government Securities Business Days preceding the first Floating Rate Interest Payment Date for the 2028 Floating Rate Notes
    Redemption Provisions:    The 2028 Floating Rate Notes will not be redeemable prior to their maturity
    Calculation Agent:    Initially, Deutsche Bank Trust Company Americas
    CUSIP / ISIN:    532457 DH8 / US532457DH81
    The 2029 Floating Rate Notes   
    Principal Amount Offered:    $500,000,000
    Maturity Date:    May 20, 2029


    Public Offering Price:    100.000% of principal amount, plus accrued interest, if any, from May 20, 2026
    Interest Rate Basis:    Compounded SOFR
    Spread to Compounded SOFR:    +46 basis points
    Interest Payment Dates:    February 20, May 20, August 20 and November 20 of each year, commencing August 20, 2026
    Interest Reset Dates:    Each Floating Rate Interest Payment Date
    Initial Interest Rate:    The initial interest rate will be Compounded SOFR determined on August 18, 2026, plus 46 basis points
    Interest Determination Date:    The second U.S. Government Securities Business Day preceding each Floating Rate Interest Payment Date
    Interest Period:    The period from and including a Floating Rate Interest Payment Date to, but excluding, the immediately succeeding Floating Rate Interest Payment Date (such succeeding Floating Rate Interest Payment Date, the “Latter Floating Rate Interest Payment Date”); provided that (i) the initial interest period for the 2029 Floating Rate Notes will be the period from and including the Settlement Date to, but excluding, the immediately succeeding Floating Rate Interest Payment Date for the 2029 Floating Rate Notes and (ii) the final interest period for the 2029 Floating Rate Notes will be the period from and including the Floating Rate Interest Payment Date immediately preceding the maturity date of the 2029 Floating Rate Notes to, but excluding, the maturity date of the 2029 Floating Rate Notes
    Observation Period:    The period from and including two U.S. Government Securities Business Days preceding the first date of such relevant Interest Period to but excluding two U.S. Government Securities Business Days preceding the Latter Floating Rate Interest Payment Date for such relevant Interest Period for the 2029 Floating Rate Notes; provided that the first Observation Period shall for the 2029 Floating Rate Notes be the period from and including two U.S. Government Securities Business Days preceding the Settlement Date to, but excluding, the two U.S. Government Securities Business Days preceding the first Floating Rate Interest Payment Date for the 2029 Floating Rate Notes
    Optional Redemption:    Subject to the special mandatory redemption provision described below, the Issuer may not redeem the 2029 Floating Rate Notes at its option prior to maturity
    Special Mandatory Redemption:    In the event that (x) the Centessa Acquisition is not consummated on or prior to the date that is five (5) business days after the later of (i) March 31, 2027 or (ii) any later date as the parties to the Centessa Agreement may agree as the “Outside Date” thereunder or (y) the Issuer notifies the trustee in writing that the Issuer will not pursue the consummation of the Centessa Acquisition, the Issuer will be required to redeem the 2029 Floating Rate Notes then outstanding at a redemption price equal to 101% of the principal amount of such 2029 Floating Rate Notes plus accrued and unpaid interest, if any, to, but excluding, the Centessa Special Mandatory Redemption Date
    Calculation Agent:    Initially, Deutsche Bank Trust Company Americas
    CUSIP / ISIN:    532457 DJ4 / US532457DJ48


    The 2029 Notes   
    Principal Amount Offered:    $750,000,000
    Maturity Date:    May 20, 2029
    Coupon:    4.150% per year
    Public Offering Price:    99.941% of principal amount, plus accrued interest, if any, from May 20, 2026
    Yield to Maturity:    4.171%
    Benchmark Treasury:    UST 3.875% due April 15, 2029
    Spread to Benchmark Treasury:    T + 28 basis points
    Benchmark Treasury Price and Yield:    99-30+ / 3.891%
    Interest Payment Dates:    May 20 and November 20 of each year, commencing November 20, 2026
    Redemption Provisions:   

    Make-whole call:

       At any time prior to April 20, 2029 at a discount rate of Treasury plus 5 basis points

    Par call:

       On or after April 20, 2029 at 100%
    Special Mandatory Redemption:    In the event that (x) the Centessa Acquisition is not consummated on or prior to the date that is five (5) business days after the later of (i) March 31, 2027 or (ii) any later date as the parties to the Centessa Agreement may agree as the “Outside Date” thereunder or (y) the Issuer notifies the trustee in writing that the Issuer will not pursue the consummation of the Centessa Acquisition, the Issuer will be required to redeem the 2029 Notes then outstanding at a redemption price equal to 101% of the principal amount of such 2029 Notes plus accrued and unpaid interest, if any, to, but excluding, the Centessa Special Mandatory Redemption Date
    CUSIP / ISIN:    532457 DK1 / US532457DK11
    The 2031 Notes   
    Principal Amount Offered:    $1,500,000,000
    Maturity Date:    May 20, 2031
    Coupon:    4.375% per year
    Public Offering Price:    99.893% of principal amount, plus accrued interest, if any, from May 20, 2026
    Yield to Maturity:    4.399%
    Benchmark Treasury:    UST 3.875% due April 30, 2031
    Spread to Benchmark Treasury:    T + 40 basis points
    Benchmark Treasury Price and Yield:    99-14 1⁄4 / 3.999%
    Interest Payment Dates:    May 20 and November 20 of each year, commencing November 20, 2026
    Redemption Provisions:   

    Make-whole call:

       At any time prior to April 20, 2031 at a discount rate of Treasury plus 10 basis points

    Par call:

       On or after April 20, 2031 at 100%


    Special Mandatory Redemption:    In the event that (x) the Centessa Acquisition is not consummated on or prior to the date that is five (5) business days after the later of (i) March 31, 2027 or (ii) any later date as the parties to the Centessa Agreement may agree as the “Outside Date” thereunder or (y) the Issuer notifies the trustee in writing that the Issuer will not pursue the consummation of the Centessa Acquisition, the Issuer will be required to redeem the 2031 Notes then outstanding at a redemption price equal to 101% of the principal amount of such 2031 Notes plus accrued and unpaid interest, if any, to, but excluding, the Centessa Special Mandatory Redemption Date
    CUSIP / ISIN:    532457 DL9 / US532457DL93
    The 2033 Notes   
    Principal Amount Offered:    $1,250,000,000
    Maturity Date:    May 20, 2033
    Coupon:    4.650% per year
    Public Offering Price:    99.982% of principal amount, plus accrued interest, if any, from May 20, 2026
    Yield to Maturity:    4.653%
    Benchmark Treasury:    UST 4.125% due April 30, 2033
    Spread to Benchmark Treasury:    T + 48 basis points
    Benchmark Treasury Price and Yield:    99-22 3⁄4 / 4.173%
    Interest Payment Dates:    May 20 and November 20 of each year, commencing November 20, 2026
    Redemption Provisions:   

    Make-whole call:

       At any time prior to March 20, 2033 at a discount rate of Treasury plus 10 basis points

    Par call:

       On or after March 20, 2033 at 100%
    Special Mandatory Redemption:    In the event that (x) the Centessa Acquisition is not consummated on or prior to the date that is five (5) business days after the later of (i) March 31, 2027 or (ii) any later date as the parties to the Centessa Agreement may agree as the “Outside Date” thereunder or (y) the Issuer notifies the trustee in writing that the Issuer will not pursue the consummation of the Centessa Acquisition, the Issuer will be required to redeem the 2033 Notes then outstanding at a redemption price equal to 101% of the principal amount of such 2033 Notes plus accrued and unpaid interest, if any, to, but excluding, the Centessa Special Mandatory Redemption Date
    CUSIP / ISIN:    532457 DM7 / US532457DM76

     

    The 2036 Notes   
    Principal Amount Offered:    $1,500,000,000
    Maturity Date:    May 20, 2036
    Coupon:    4.850% per year
    Public Offering Price:    99.640% of principal amount, plus accrued interest, if any, from May 20, 2026
    Yield to Maturity:    4.896%


    Benchmark Treasury:    UST 4.125% due February 15, 2036
    Spread to Benchmark Treasury:    T + 55 basis points
    Benchmark Treasury Price and Yield:    98-08 / 4.346%
    Interest Payment Dates:    May 20 and November 20 of each year, commencing November 20, 2026
    Redemption Provisions:   

    Make-whole call:

       At any time prior to February 20, 2036 at a discount rate of Treasury plus 10 basis points

    Par call:

       On or after February 20, 2036 at 100%
    Special Mandatory Redemption:    In the event that (x) the Centessa Acquisition is not consummated on or prior to the date that is five (5) business days after the later of (i) March 31, 2027 or (ii) any later date as the parties to the Centessa Agreement may agree as the “Outside Date” thereunder or (y) the Issuer notifies the trustee in writing that the Issuer will not pursue the consummation of the Centessa Acquisition, the Issuer will be required to redeem the 2036 Notes then outstanding at a redemption price equal to 101% of the principal amount of such 2036 Notes plus accrued and unpaid interest, if any, to, but excluding, the Centessa Special Mandatory Redemption Date
    CUSIP / ISIN:    532457 DR6 / US532457DR63

     

    The 2056 Notes   
    Principal Amount Offered:    $1,750,000,000
    Maturity Date:    May 20, 2056
    Coupon:    5.600% per year
    Public Offering Price:    99.726% of principal amount, plus accrued interest, if any, from May 20, 2026
    Yield to Maturity:    5.619%
    Benchmark Treasury:    UST 4.625% due November 15, 2055
    Spread to Benchmark Treasury:    T + 68 basis points
    Benchmark Treasury Price and Yield:    95-04+ / 4.939%
    Interest Payment Dates:    May 20 and November 20 of each year, commencing November 20, 2026
    Redemption Provisions:   

    Make-whole call:

       At any time prior to November 20, 2055 at a discount rate of Treasury plus 12.5 basis points

    Par call:

       On or after November 20, 2055 at 100%
    CUSIP / ISIN:    532457 DP0 / US532457DP08

     

    The 2066 Notes   
    Principal Amount Offered:    $1,000,000,000
    Maturity Date:    May 20, 2066
    Coupon:    5.700% per year
    Public Offering Price:    99.391% of principal amount, plus accrued interest, if any, from May 20, 2026
    Yield to Maturity:    5.739%


    Benchmark Treasury:    UST 4.625% due November 15, 2055
    Spread to Benchmark Treasury:    T + 80 basis points
    Benchmark Treasury Price and Yield:    95-04+ / 4.939%
    Interest Payment Dates:    May 20 and November 20 of each year, commencing November 20, 2026
    Redemption Provisions:   

    Make-whole call:

       At any time prior to November 20, 2065 at a discount rate of Treasury plus 15 basis points

    Par call:

       On or after November 20, 2065 at 100%
    CUSIP / ISIN:    532457 DQ8 / US532457DQ80

     

     

     

    *

    A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.

    **

    Under Rule 15c6-1 under the Securities Exchange Act of 1934, as amended, trades in the secondary market are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the Notes prior to delivery will be required, by virtue of the fact that the Notes initially will settle in T+10, to specify an alternative settlement cycle at the time of any such trade to prevent failed settlement and should consult their own advisors.

    The Issuer has filed a registration statement (No. 333-285052) (including a prospectus) with the Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the preliminary prospectus relating to this offering and the other documents the Issuer has filed with the SEC for more complete information about the Issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, the Issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus and the prospectus supplement if you request it by calling Morgan Stanley & Co. LLC at +1-866-718-1649, Citigroup Global Markets Inc. at +1-800-831-9146, Deutsche Bank Securities Inc. at +1-800-503-4611 or Goldman Sachs & Co. LLC at +1-866-471-2526.

    ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.

    Get the next $LLY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LLY

    DatePrice TargetRatingAnalyst
    3/17/2026$850.00Hold → Reduce
    HSBC Securities
    2/25/2026$1250.00Outperform
    RBC Capital Mkts
    2/20/2026$1350.00Overweight
    Barclays
    1/7/2026$1250.00Buy
    UBS
    12/16/2025$1230.00Neutral → Buy
    Daiwa Securities
    12/15/2025$951.00 → $1145.00Buy
    Goldman
    12/15/2025$1286.00 → $1268.00Buy
    BofA Securities
    11/13/2025$1165.00Sector Outperform
    Scotiabank
    More analyst ratings

    $LLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Pres., Lilly Oncology Van Naarden Jacob bought $647,360 worth of shares (1,000 units at $647.36), increasing direct ownership by 5% to 20,562 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/13/25 4:15:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Eli Lilly downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Eli Lilly from Hold to Reduce and set a new price target of $850.00

    3/17/26 7:55:56 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Eli Lilly with a new price target

    RBC Capital Mkts initiated coverage of Eli Lilly with a rating of Outperform and set a new price target of $1,250.00

    2/25/26 7:51:49 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Eli Lilly with a new price target

    Barclays initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $1,350.00

    2/20/26 8:24:27 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    12/5/23 5:00:21 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

    DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer. The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary Session at the 2026 ASCO Annual Meeting and will be simultaneously published in The New England Journal of Medicine. For investors, the

    6/1/26 9:05:00 AM ET
    $LLY
    $NTHI
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care

    Phase 3 ACHIEVE results showed Foundayo, an oral GLP-1 taken without food or water restrictions, outperformed oral semaglutide and dapagliflozin in type 2 diabetes, reinforcing its potential to redefine oral incretin therapyNew analyses of the ATTAIN program highlight Foundayo's profile in patient populations central to the future of cardiometabolic care, including women at every stage of menopausePivotal Phase 3 results showed retatrutide, a first-in-class triple receptor agonist, delivered powerful results in obesity, type 2 diabetes and other complicationsINDIANAPOLIS, May 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide), Mounjaro (tirzepatide

    5/28/26 1:00:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Foundayo and Zepbound now covered for millions of Americans

    CVS Caremark begins covering Foundayo June 1 and resumes Zepbound coverage by October 1 Eligible patients may pay as low as $25 a month for their medicineINDIANAPOLIS, May 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced an access milestone in obesity care: all three of the nation's largest pharmacy benefit managers (PBMs) will cover Lilly's full obesity medicine portfolio. This significantly expands the number of Americans who can access FDA-approved options through their existing insurance."For too long, effective obesity treatment has been out of reach for the people who need it," said Ilya Yuffa, executive vice president and president of Lilly USA and global cust

    5/28/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    SEC Filings

    View All

    SEC Form 8-K filed by Eli Lilly and Company

    8-K - ELI LILLY & Co (0000059478) (Filer)

    5/20/26 4:30:32 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SD filed by Eli Lilly and Company

    SD - ELI LILLY & Co (0000059478) (Filer)

    5/11/26 4:30:32 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly and Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - ELI LILLY & Co (0000059478) (Filer)

    5/7/26 4:41:48 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sulzberger Gabrielle was granted 5 shares, increasing direct ownership by 0.17% to 2,987 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    5/19/26 4:19:57 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Luciano Juan R was granted 16 shares, increasing direct ownership by 0.10% to 16,851 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    5/19/26 4:18:50 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fyrwald J Erik was granted 10 shares, increasing direct ownership by 0.01% to 75,280 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    5/19/26 4:17:48 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Financials

    Live finance-specific insights

    View All

    Lilly declares second-quarter 2026 dividend

    INDIANAPOLIS, May 4, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2026 of $1.73 per share on outstanding common stock.The dividend is payable on June 10, 2026, to shareholders of record at the close of business on May 15, 2026.About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to

    5/4/26 11:11:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines

    Revenue in Q1 2026 increased 56% to $19.8 billion primarily driven by volume growth, partially offset by lower realized prices from Mounjaro and Zepbound.Q1 2026 EPS increased by 170% to $8.26 on a reported basis and increased by 156% to $8.55 on a non-GAAP basis. The Q1 2026 reported and non-GAAP EPS included $0.52 of acquired IPR&D charges compared to $1.72 in Q1 2025.Increased 2026 full-year revenue guidance to be in the range of $82.0 billion to $85.0 billion and non-GAAP EPS guidance to be in the range of $35.50 to $37.00.Regulatory progress included U.S. FDA approval of Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems. Pipeline progres

    4/30/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

    Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi

    4/23/26 6:15:00 AM ET
    $LGVN
    $LLY
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LLY
    Leadership Updates

    Live Leadership Updates

    View All

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

    INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Ho brings more than 20 years of biopharmaceutical experience leading therapeutic development across neurology, rare diseases, immunology, and other areas. Most recently, she served as chief medical officer an

    11/6/25 4:05:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly to Acquire Adverum Biotechnologies

    Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose  Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases  INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adve

    10/24/25 8:30:00 AM ET
    $ADVM
    $LLY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $LLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    10/23/24 5:17:34 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    2/13/24 5:04:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    1/26/24 4:25:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care